Cart (0)
Your shopping cart is empty!
Kagocel N20 tab
Kagocel N20 tab
Product Code: kagocel-20

Kagocel N20 tab

Compare this Product
$14.50
In Stock
Structure
1 tab.:
- kagocel 12 mg
Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, ludipress (direct compression lactose with the composition: lactose monohydrate, povidone (collidone 30), crospovidone (collidone CL)) - before receiving the tablet weighing 100 mg.

pharmachologic effect
The main mechanism of action of Kagocel® is the ability to induce the production of interferon. Kagocel® causes the formation in the human body of the so-called late interferon, which is a mixture of α and β interferons with high antiviral activity. 
Kagocel® induces the production of interferon in almost all populations of cells participating in the antiviral response of the body: T and B lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When ingesting a single dose of Kagocel®, the serum interferon titer reaches its maximum value after 48 hours. 
The interferon response of the body to the administration of Kagocel® is characterized by a prolonged (up to 4-5 days) circulation of interferon in the bloodstream. The dynamics of the accumulation of interferon in the intestine when ingested Kagocel® does not coincide with the dynamics of titers of circulating interferon. In serum, the production of interferon reaches high values ​​only 48 hours after taking Kagocel®, while in the intestine the maximum production of interferon is noted after 4 hours.
Kagocel®, when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, is not carcinogenic, and does not have an embryotoxic effect.

Indications
Kagocel® is used in adults as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes.
Kagocel® is used in children from the age of 6 years as a prophylactic for influenza and other acute respiratory viral infections.
Kagocel® is used in children from the age of 3 years as a therapeutic agent for influenza and other acute respiratory viral infections.

Contraindications
Increased individual sensitivity, pregnancy, age up to 3 years, lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Side effects
Perhaps the development of allergic reactions.

Interaction
Kagocel® is well combined with other antiviral drugs, immunomodulators and antibiotics (additive effect).

How to take, course of administration and dosage
For oral use.
For the treatment of influenza and SARS, adults are prescribed in the first two days - 2 tablets of Kagocel 3 times a day, in the next two days - one tablet 3 times a day. Total for the course - 18 tablets, the duration of the course is 4 days.
Prevention of influenza and SARS in adults is carried out in 7-day cycles: two days - 2 tablets 1 time per day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.
For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. In total, 30 tablets per course, the duration of the course is 5 days.
For the treatment of influenza and SARS, children aged 3 to 6 years are prescribed in the first two days - 1 tablet of Kagocel 2 times a day, in the next two days - one tablet 1 time per day. In total for the course - 6 tablets, the duration of the course is 4 days.
For the treatment of influenza and SARS, children over the age of 6 are prescribed in the first two days - 1 tablet 3 times a day, in the next two days - one tablet 2 times a day. In total, 10 tablets per course, the duration of the course is 4 days.
Prevention of influenza and SARS in children over the age of 6 years is carried out in 7-day cycles: two days - 1 tablet of Kagocel once a day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.

Overdose
In case of accidental overdose, it is recommended to prescribe a plentiful drink, cause vomiting.

Special instructions
To achieve a therapeutic effect, Kagocel® should be started no later than the fourth day from the onset of the disease.

Release form
Tablets, round, biconvex, cream color, interspersed.

Storage conditions
In a dry, dark place at a temperature of no higher than 25 ° C

Shelf life
2 years